Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN22044 in Healthy Adult Participants
NCT07526116Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REGN22044 (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of Treatment-Emergent Adverse Events at 18 weeks and Severity of Treatment-Emergent Adverse Events at 18 weeks. Started Jun 2026; status: recruiting.
02
Drugs
REGN22044
Beyond the preview
Go deeper on NCT07526116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07526116.